Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ricrolin+

Phase 3Small molecule

IIcahn School of Medicine at Mount Sinai

Ricrolin+ is one of 63 small molecule programs targeting Tic Disorder. It is currently in Phase 3.

2

Indications

2

Total Trials

0

Active Trials

62

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tic DisorderActive, not recruiting

KeratoconusActive, not recruiting

Tic DisorderPhase 3

Active, not recruiting

KeratoconusPhase 3

Active, not recruiting

Competition

Competitive Landscape

71 competitors in Tic Disorder

#DrugCompanyPhaseTrials

Zyprexa

Intuniv

PPromius Pharma, LLC

Buspar

Bristol-Myers Squibb

Abilify

Vitrakvi

Lynparza

Ibrance

Balversa

Johnson & Johnson

Retevmo

Haldol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tic Disorder1 trial

Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders

Unknown status·CCenter for Sight, Sacramento, CA·Phase 3·NCT03858036·550 enrolled

Keratoconus1 trial

Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia

Unknown status·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT03080077·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ricrolin+. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ricrolin+ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ricrolin+. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIcahn School of Medicine at Mount Sinai

Related News